Dengue fever future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
{{Dengue fever}}
{{Dengue fever}}
{{CMG}}
{{CMG}}

Revision as of 13:50, 8 June 2014

Dengue Fever Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Dengue fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Dengue fever future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Dengue fever future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Dengue fever future or investigational therapies

CDC on Dengue fever future or investigational therapies

Dengue fever future or investigational therapies in the news

Blogs on Dengue fever future or investigational therapies

Directions to Hospitals Treating Dengue fever

Risk calculators and risk factors for Dengue fever future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Although there is no commercially available vaccine, there are several ongoing vaccine development programs.

Vaccine development

There is no commercially available vaccine for the dengue flavivirus. However, one of the many ongoing vaccine development programs is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries.[1] Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers.[2] and a number of other vaccine candidates are entering phase I or II testing.[3]

Inhibitors of Viral Replication

Emerging evidence suggests that mycophenolic acid and ribivirin inhibit dengue replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.[2] In vivo studies, however, have not yet been done.


References

  1. "Pediatric Dengue Vaccine Initiative website".
  2. "Thailand to test Mahidol-developed dengue vaccine prototype". People's Daily Online. 2005-09-05. Retrieved 2006-10-08.
  3. Edelman R (2007). "Dengue vaccines approach the finish line". Clin Infect Dis. 45 (S1): S56&ndash, S60. doi:10.1086/518148.